title: Prognosis and therapy of early acute idiopathic auditory failure.
abstract: The prognostic value of some otovestibular parameters was evaluated in 46 cases of acute idiopathic hypoacusis (AIH) and 12 cases of acute idiopathic anacusis (AIA) observed within 7 days of the onset. Recovery in AIH is predicted by some otoneurological parameters as mean pure-tone hearing threshold (PTA) for 500, 1,000 and 2,000 Hz, stapedial reflex and severe vertigo. None of these measures alone seems to have prognostic value. The expected recovery rate also is reflected in the various parameters taken as a whole. Subjects with mean PTA better than 70 dB HL together with stapedius reflex present for 500 and 1,000 Hz, no decay and no vertigo have a very favourable prognosis: 86% had complete or good recovery. On the contrary, subjects with mean PTA worse than 70 dB HL and with pathological stapedius reflex have a generally unfavourable prognosis: 35% had complete or good recovery. Vertigo as a symptom does not seem in itself to have an unfavourable prognostic value. Actually, patients with severe vertigo generally have a poor recovery. Vertigo as a symptom indeed is frequently associated with a more severe sensorineural lesion. Carbogen or heparin-dextran are not an effective treatment: complete-good global recoveries obtained in AIH without any treatment, with carbogen or with heparin-dextran were, respectively, 65, 68 and 62%. As a consequence, an early therapy with these substances has no apparent value. Patients affected with AIA have a very unfavourable prognosis. All of our patients with AIA had poor recovery. For the moment we feel it is easier to reach a satisfactory prognosis rather than to institute an effective or causal therapy in acute idiopathic auditory failure.
authors: Department of Otolaryngology, University of Trieste, Italy.
authors: M
authors: M
authors: Russolo
authors: M
authors: M
authors: Bianchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001301:Audiometry, Pure-Tone; D002245:Carbon Dioxide / Q000627:therapeutic use*; D003638:Deafness / Q000188:drug therapy*; D003911:Dextrans / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D034381:Hearing Loss / Q000150:complications / Q000188:drug therapy*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000627:therapeutic use*; D011379:Prognosis; D014717:Vertigo / Q000209:etiology
chemical_list: D003911:Dextrans; D002245:Carbon Dioxide; C011700:carbogen; D006493:Heparin; D010100:Oxygen